Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland.
+ 2 more risks
Weak fundamentals or lack of information.
Share Price & News
How has Faron Pharmaceuticals Oy's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FARN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: FARN exceeded the UK Biotechs industry which returned 8.2% over the past year.
Return vs Market: FARN exceeded the UK Market which returned 7.1% over the past year.
Price Volatility Vs. Market
How volatile is Faron Pharmaceuticals Oy's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Percentage Of Faron Pharmaceuticals Oy (LON:FARN) Shares Do Insiders Own?
3 months ago | Simply Wall StCan You Imagine How Chuffed Faron Pharmaceuticals Oy's (LON:FARN) Shareholders Feel About Its 130% Share Price Gain?
4 months ago | Simply Wall StWhat Kind Of Share Price Volatility Should You Expect For Faron Pharmaceuticals Oy (LON:FARN)?
Is Faron Pharmaceuticals Oy undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: FARN (£2.8) is trading above our estimate of fair value (£0.28)
Significantly Below Fair Value: FARN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FARN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: FARN is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FARN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FARN has negative assets, so we can't compare its PB Ratio to the GB Biotechs industry average.
How is Faron Pharmaceuticals Oy forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if FARN's forecast earnings growth is above the savings rate (0.5%).
Earnings vs Market: Insufficient data to determine if FARN's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: FARN is forecast to have no revenue next year.
High Growth Revenue: FARN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FARN's Return on Equity is forecast to be high in 3 years time
How has Faron Pharmaceuticals Oy performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FARN is currently unprofitable.
Growing Profit Margin: FARN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FARN is unprofitable, and losses have increased over the past 5 years at a rate of -38.2% per year.
Accelerating Growth: Unable to compare FARN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FARN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: FARN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Faron Pharmaceuticals Oy's financial position?
Financial Position Analysis
Short Term Liabilities: FARN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: FARN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: FARN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: FARN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: FARN has a low level of unsold assets or inventory.
Debt Coverage by Assets: FARN has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FARN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FARN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -38.5% each year
What is Faron Pharmaceuticals Oy's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate FARN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate FARN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FARN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FARN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FARN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Markku Jalkanen (64yo)
Prof. Markku Jalkanen, Ph.D., serves as a Partner and Advisor at Inveni Capital. Prof. Jalkanen founded Faron Pharmaceuticals Corp. (formerly Faron Pharmaceuticals Ltd.) in 2006 and Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: Markku's total compensation ($USD0.00) is below average for companies of similar size in the UK market ($USD588.44K).
Compensation vs Earnings: Markku's compensation has increased whilst the company is unprofitable.
|Vice President of Financing & Investor Relations||0.7yrs||€216.93k||0.17% €209.0k|
|Chief Development Officer||1.1yrs||€360.62k||2.53% €3.1m|
|Chief Financial Officer||0.7yrs||no data||no data|
|Vice President of Operations||0yrs||no data||no data|
|Chief Medical Officer & VP of Drug Development||3.8yrs||no data||no data|
|Chief Commercial Officer||2.1yrs||no data||no data|
|Regulatory Consultant||3yrs||no data||no data|
Experienced Management: FARN's management team is considered experienced (2.1 years average tenure).
|Chairman of Matins Scientific Advisory Board||1.4yrs||€33.69k||0.28% €333.8k|
|Non-Executive Director||2.8yrs||€46.70k||0.042% €50.4k|
|Board Observer||1.4yrs||€36.20k||0.0092% €11.2k|
|Non-Executive Chairman||4.4yrs||€77.79k||0.052% €62.7k|
|Non-Executive Vice-Chairman||4.4yrs||€44.42k||1.17% €1.4m|
|Non-Executive Director||2.8yrs||€48.21k||no data|
|Member of Matins Scientific Advisory Board||0.4yrs||no data||no data|
|Non-Executive Director||4.4yrs||€43.14k||0.040% €48.9k|
|Member of Matins Scientific Advisory Board||0.4yrs||no data||no data|
Experienced Board: FARN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.2%.
Faron Pharmaceuticals Oy's company bio, employee growth, exchange listings and data sources
- Name: Faron Pharmaceuticals Oy
- Ticker: FARN
- Exchange: AIM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£121.214m
- Shares outstanding: 43.29m
- Website: https://www.faron.com
Number of Employees
- Faron Pharmaceuticals Oy
- Joukahaisenkatu 6
- Finland Proper
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FARN||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Nov 2015|
|FARON||HLSE (OMX Nordic Exchange Helsinki)||Yes||Ordinary Shares||FI||EUR||Nov 2015|
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company’s lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It also develops Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 23:02|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.